Autologous Stem Cell Rescue for Primary Amyloidosis
- Conditions
- AmyloidosisBlood and Marrow Transplant (BMT)
- Registration Number
- NCT00186407
- Lead Sponsor
- Stanford University
- Brief Summary
To evaluate the role of high dose therapy and autologous hematopoietic cell transplant for amyloidosis.
- Detailed Description
To learn about the use of high dose chemotherapy followed by transplantation using peripheral blood stem cells.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 50
-
Primary amyloidosis
-
Age < 75 years.
-
Patients must have their pathology reviewed and the diagnosis confirmed at Stanford University Medical Center.
-
Patients who have undergone bone marrow transplantation previously will not be eligible.
-
Patients must have a Karnofsky performance status greater than 70%.
-
Patients must have a serum creatinine less than 2 mg/dl or creatinine clearance greater than 30 ml/min, bilirubin less than 2 mg/dl, transaminases less than two times normal, left ventricular ejection fraction >45% on echocardiography, cardiac index > 1.8 liters/min/m^2 and pulmonary function tests demonstrating FEV1 and DLCO > 60%.
-
Patients must be HIV negative.
-
Pregnant or lactating women will not be eligible to participate.
-
Patients must provide signed informed consent.
-
Patients with multiple myeloma and amyloid are eligible.
- prior blood or marrow transplant
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method To evaluate the role of high dose therapy and autologous hematopoietic cell transplant for amyloidosis
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Stanford University School of Medicine
🇺🇸Stanford, California, United States